[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632522":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":46,"centralContacts":51,"locations":61,"responsibleParty":77,"collaborators":45,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":45,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":45,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":45,"overallStatus":64,"whyStopped":45,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"JW Pharmaceutical","INDUSTRY",[8,15,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: SAD","EXPERIMENTAL","Up to five cohorts (S1-S5) (n = 40). Conducted in healthy Korean adults.",[13,14],"Drug: JW0061 SAD","Drug: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"Part 1: MAD","Up to five cohorts (M1-M5) (n = 40). Conducted in healthy Korean adults.",[19,14],"Drug: JW0061 MAD",{"label":21,"type":10,"description":22,"interventionNames":23},"Part 2: SAD","Up to two cohorts (S6-S7) (n = 12). Conducted in healthy Caucasian adults.",[13],{"label":25,"type":10,"description":26,"interventionNames":27},"Part 2: MAD","Up to two cohorts (M6-M7) (n = 12). Conducted in healthy Caucasian adults.",[19],[29,36,41],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","JW0061 SAD","Single ascending doses",[9,21],[35],"JW0061",{"type":30,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"JW0061 MAD","Multiple ascending doses",[16,25],[35],{"type":30,"name":42,"description":43,"armGroupLabels":44,"otherNames":45},"Placebo","Matching placebo for JW0061",[16,9],null,[47],{"name":48,"affiliation":49,"role":50},"Seung Hwan Lee","Seoul National University Hospital","PRINCIPAL_INVESTIGATOR",[52,57],{"name":53,"role":54,"phone":55,"phoneExt":45,"email":56},"Soyeon Jeong","CONTACT","+82-2-840-6797","soyoun1628@jwhealthcare.com",{"name":58,"role":54,"phone":59,"phoneExt":45,"email":60},"Inyoung Park","+82-2-840-6887","inyoung.park@jwhealthcare.com",[62],{"facility":63,"status":64,"city":65,"state":65,"zip":66,"country":67,"countryCode":45,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"Seoul National University Hospital Clinical Trial Center","RECRUITING","Seoul","110-744","South Korea",{"type":69,"coordinates":70},"Point",[71,72],126.9784,37.566,{"lat":72,"lon":71},[75],{"name":76,"role":50,"phone":45,"phoneExt":45,"email":45},"SeungHwan Lee",{"type":78,"investigatorFullName":45,"investigatorTitle":45,"investigatorAffiliation":45,"oldNameTitle":45,"oldOrganization":45},"SPONSOR","100632522","phase-1-to-evaluate-the-safety-pharmacokinetic-and-pharmacodynamics-of-jw0061-in-healthy-volunteers-100632522",false,"NCT07514780","To Evaluate the Safety, Pharmacokinetic and Pharmacodynamics of JW0061 in Healthy Volunteers","A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Clinical Trial to Evaluate the Safety, Pharmacokinetic and Pharmadynamics of JW0061 Following Topical Application in Korean and Caucasians Healthy Adults","Inclusion Criteria:\n\n* Body weight between 50.0 kg and 90.0 kg, and BMI between 18.5 and 29.9 kg\u002Fm².\n* Determined to be healthy and eligible by the investigator based on medical history, physical examination, and clinical laboratory tests.\n* Capable of providing written informed consent and willing to comply with all study requirements and restrictions.\n\nExclusion Criteria:\n\n* Presence of clinically significant scalp conditions that may interfere with safety assessments.\n* History of malignancy within 5 years prior to screening.\n* History of hypersensitivity or allergy to the study drug or its components.",true,"ALL","19 Years","55 Years",{"count":91,"type":92},104,"ESTIMATED","INTERVENTIONAL",[95],"PHASE1","This clinical study is a phase 1, randomized, double-blind, placebo-controlled, dose escalation clinical trial to evaluate the safety, pharmacokinetic and pharmacodynamics of JW0061 following topical application in Korean and Caucasians healthy adults.",[98],"Healthy","2026-04-20",{"date":101,"type":102},"2026-04-23","ACTUAL",{"date":104,"type":102},"2026-04-13",{"date":106,"type":92},"2027-04-30",{"name":5,"class":6},1]